AEPA empowered to protect Basmati from patent violations: related news

U.S. Patent Office allows another significant VNUS patent

Add our medical news to digg - U.S. Patent Office allows another significant VNUS patent Add our medical news to NewsVine - U.S. Patent Office allows another significant VNUS patent Add our medical news to Fark - U.S. Patent Office allows another significant VNUS patent Add our medical news to Furl - U.S. Patent Office allows another significant VNUS patent Add our medical news to Shadows - U.S. Patent Office allows another significant VNUS patent Add our medical news to YahooMyWeb - U.S. Patent Office allows another significant VNUS patent Add our medical news to Reddit -U.S. Patent Office allows another significant VNUS patent Add our medical news to StumbleUpon - U.S. Patent Office allows another significant VNUS patent Add our medical news to Facebook - U.

AEPA empowered to protect Basmati from patent violations

New Delhi, May 15: Government on Thursday decided to empower the Agriculture Export Promotion Agency to protect India’s farm and horticulture products like Basmati rice from anyone patenting them anywhere in the world.

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

Barr confirms Entocort patent challenge

Add our medical news to digg - Barr confirms Entocort patent challenge Add our medical news to NewsVine - Barr confirms Entocort patent challenge Add our medical news to Fark - Barr confirms Entocort patent challenge Add our medical news to Furl - Barr confirms Entocort patent challenge Add our medical news to Shadows - Barr confirms Entocort patent challenge Add our medical news to YahooMyWeb - Barr confirms Entocort patent challenge Add our medical news to Reddit -Barr confirms Entocort patent challenge Add our medical news to StumbleUpon - Barr confirms Entocort patent challenge Add our medical news to Facebook - Barr confirms Entocort patent challenge

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

Nintendo Loses Patent Suit In East Texas, Of Course

The latest in a long line of patent lawsuits in every patent hoarders favorite district of East Texas involves the game controllers used by Nintendo. A company holds a patent on a 3D controller and sued Nintendo (and Microsoft) for supposedly violating the patent. Not surprisingly, the jury found in favor of the patent holder. Juries quite often side with the patent holder, no matter how questionable the patent may be. In this case, there would seem to be a ton of prior art raising validity questions. The patent itself was filed in November of 2000, at which point there were already numerous game controllers that seem to meet most of the criteria outlined in the claims. Whatever minor differences there may have been between what was on the market and what's in the claims should be seen as an obvious iteration of game controllers.

febit receives U.S. patent for microfluidic extraction method

Add our medical news to digg - febit receives U.S. patent for microfluidic extraction method Add our medical news to NewsVine - febit receives U.S. patent for microfluidic extraction method Add our medical news to Fark - febit receives U.S. patent for microfluidic extraction method Add our medical news to Furl - febit receives U.S. patent for microfluidic extraction method Add our medical news to Shadows - febit receives U.S. patent for microfluidic extraction method Add our medical news to YahooMyWeb - febit receives U.S. patent for microfluidic extraction method Add our medical news to Reddit -febit receives U.S. patent for microfluidic extraction method Add our medical news to StumbleUpon - febit receives U.S. patent for microfluidic extraction method Add our medical news to Facebook - febit receives U.

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms...

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems (NASDAQ: NICE) announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision. The court rejected Verint's claims challenging the validity of NICE's patent and reaffirmed its validity. The US Patent Office has also, prior to the trial, denied Verint's request for re-examination of the same patent.

Judge Puts JPEG Patent On Ice

The infamous and questionable JPEG patent held by Global Patent Holdings (GPH) and used to threaten just about anyone online (including the Green Bay Packers, CDW, a resort in Florida and others) who happened to have a JPEG on their website has been put on hold for a while. While the folks behind it somehow got Forbes to write a puff piece making it sound like the patent holder was the victim, if you look at the details, it was clear that this was an abuse of the patent system. It was a questionable patent from the beginning, and an earlier review of the patent had every claim thrown out. However, during that process, the patent holder tried adding a ton of other claims -- one of which the USPTO actually allowed to go through. It's that single remaining claim that's being used to sue lots of folks.

U.S. Patent Office Allows Another Significant VNUS Patent

SAN JOSE, Calif., May 9 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. today announced that the U.S. Patent & Trademark Office has decided to allow a second continuation patent application related to the patents in the VNUS patent infringement lawsuit against suppliers of endovenous laser products. This comes on the heels of the Patent Office's decision last month to allow VNUS a separate patent application, also filed as a continuation of one of the patents in the lawsuit.

U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent

NEW YORK--(BUSINESS WIRE)--April 30, 2008 - Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response to a request by a law firm that represented the generic company Ranbaxy Laboratories Limited. The patent, which expires in March 2010 (including pediatric exclusivity), was previously the subject of litigation against Ranbaxy, in which Pfizer prevailed in both the trial and appeal courts.

Patent Office now completes Microsoft's review for patent re-examination of complete Avistar U.S. patent portfolio - Quick facts

Patent Office now completes review of Microsoft's requests for patent re-examination of complete Avistar (AVSR) U.S. patent portfolio

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

Patent Appeals System Under Constitutional Attack

Goobermunch sends in a law.com article going into questions about the validity of recent patent rulings (within the past eight years) by the Board of Patent Appeals and Interferences, due to the unconstitutionality of the method for appointing patent and trademark appeals judges. The problem arises because the patent appeals judges were appointed by the Director of the Patent and Trademark Office, rather than the Secretary of Commerce. Under Article 2, Section 2 of the U.S. Constitution, the power to appoint "inferior officers" of the government may be vested in "in the President alone, in the courts of law, or in the heads of departments." The patent appeals judges are likely inferior officers, and therefore must be appointed by the President, the courts, or a department head.

GPL-Violations.org and FSFE's Freedom Task Force to work more closely together

GPL-Violations.org and FSFE's Freedom Task Force to work more closely together Coordinators of the FSFE Freedom Task Force (FTF) and GPL-Violations.org recently met in Berlin to discuss future cooperation. The two organisations have agreed to deepen their partnership, building on their combined work since the launch of the FTF in October 2006. GPL-Violations.org will be pro-actively working on cases and seeking resolutions where violations occur. The FTF will continue and expand its educational and networking activities to ensure awareness of best practice and help support people with their use of the licences. "Since GPL-Violations.org was launched the software market in Europe has changed significantly," states Harald Welte, founder of GPL-Violations.

OpenPages Receives Patent for Market-Leading Enterprise GRC Software

(June 10, 2008)-- OpenPages, provider of Enterprise GRC Management Solutions that optimize business performance, today announced it has received a patent for its highly configurable GRC platform. United States Patent and Trademark Office (USPTO) awarded the company U.S. patent No 7,356,771 on April 8, 2008, and the patent describes the company's innovation around developing applications based on a metadata-driven framework. The patent demonstrates the uniqueness of the company's GRC platform and its commitment to product innovation. The patent further illustrates the company's leadership in the market for governance, risk and compliance (GRC) solutions.

The Meaningless WiMax Patent Pool

There are some folks who believe that the solution to patent problems is to just have everyone who claims to have a patent on a certain technology throw it into a "patent pool" and then those who use the technology pay up a fee that gets divided up among pool members. It sounds nice, but in practice, it almost never works. Setting up a patent pool actually encourages the wrong behavior: it encourages plenty of other patent holders to claim they deserve to be a part of the pool, and if they're not included, they start suing like crazy. Also, it encourages companies to try to get any kind of patent that might get them included in a pool, leading to all sorts of crazy claims. It's the exact opposite of the type of behavior that should be encouraged.

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

Composite Technology Announces Issuance of Key Patent

Composite Technology Corporation (CTC) (OTCBB: CPTC) announced today that its CTC Cable Corporation subsidiary has been awarded United States Patent 7,368,162. This patent protects key facets of CTC Cable's ACCC* conductor and core, as well as a wide range of potentially competing designs. The United States Patent and Trademark Office officially granted the patent on May 6, 2008. CTC Cable Corporation now holds six United States patents relating to its ACCC conductor, core and hardware accessories, with additional patent applications pending. CTC Cable Corporation is pursuing corresponding patent applications in many other countries throughout the world.

VioQuest Pharmaceuticals Announces Issuance of U.S. Patent

BASKING RIDGE, N.J.--(BUSINESS WIRE)--May 7, 2008 - VioQuest Pharmaceuticals (OTCBB:VOQP) today announced that the United States Patent and Trademark Office has issued a patent for the company's investigational product candidate Xyfid(TM) (1% topical uracil). U.S. Patent No. 7,368,456 ('456 patent), entitled "Methods, compositions, and kits for organ protection during systemic anticancer therapy," includes pharmaceutical compositions, methods of treatment, and combination kits. The '456 patent applies to the use of Xyfid as well as to a range of methods designed to protect body tissue from the toxic effects of certain systemically administered anticancer therapeutic agents.

Nortel Joins Qualcomm in Opposition to LTE Patent Pool

Last month a group of LTE product developers opted to come together to create a patent pool for the technology. The goal of the patent pool is to reduce competition in the market, prevent lengthy and expensive lawsuits related to infringement and ultimately to get LTE products to the market more quickly. Suspiciously absent from the patent pool was Qualcomm, a company which faced significant losses after various patent infringement cases last year but which is sticking to its guns in favor of allowing individual companies to patent LTE technology. Another manufacturer, Nortel, has now joined Qualcomm in opposition to the patent pool.

Search took 0.25 seconds.